In many different types of cancers, the MYC and MYCN preferentially drive the strong expression of super enhancer containing oncogenes to drive cancer progression, and it has been reported that targeting MYC driven super enhancer signaling is a promising and effective strategy for cancer therapy.3,17,18 Here in this study, we studied the potential role of MYC in osteosarcoma and found that MYC is aberrantly expressed in osteosarcoma patients and MYC expression is associated with poor osteosarcoma prognosis, therefore, our data identified MYC as a potential therapeutic target for osteosarcoma. Here, MYC is linked to osteosarcoma.